Investors Purchase Large Volume of OPKO Health Call Options (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 9,645 call options on the stock. This represents an increase of approximately 402% compared to the typical volume of 1,921 call options.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a report on Wednesday, January 8th. StockNews.com downgraded OPKO Health from a "hold" rating to a "sell" rating in a report on Wednesday, January 15th. Finally, Barrington Research restated an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 47,537 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were purchased at an average price of $1.47 per share, with a total value of $69,879.39. Following the completion of the purchase, the chief executive officer now directly owns 213,234,014 shares of the company's stock, valued at $313,454,000.58. This represents a 0.02 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 1,521,609 shares of company stock worth $2,313,710 over the last quarter. 47.26% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OPK. Rubric Capital Management LP grew its position in OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock valued at $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Millennium Management LLC boosted its position in OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock valued at $6,745,000 after buying an additional 2,112,382 shares during the period. Lazard Asset Management LLC increased its position in shares of OPKO Health by 143.6% during the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock worth $3,746,000 after acquiring an additional 1,502,342 shares during the period. Altshuler Shaham Ltd purchased a new position in OPKO Health in the fourth quarter valued at $2,082,000. Finally, Norges Bank acquired a new position in shares of OPKO Health during the fourth quarter worth about $1,657,000. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Price Performance

Shares of OPK stock traded up $0.04 during mid-day trading on Wednesday, hitting $1.68. 1,416,259 shares of the stock were exchanged, compared to its average volume of 2,729,434. OPKO Health has a 52-week low of $0.86 and a 52-week high of $1.76. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The firm has a fifty day moving average of $1.54 and a 200 day moving average of $1.55. The company has a market cap of $1.14 billion, a PE ratio of -8.87 and a beta of 1.63.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.